Novel druggable targets for brain conditions

Mapping and restoring the neuronal surface

Autism is the fastest growing developmental condition in the world, yet there are no approved drugs for the core features of autism. Complex genetics and symptom variability have made it difficult to identify drug targets.

Informed by research out of the Rockefeller University, Hebbian Bio is building a first of its kind drug target discovery approach for central nervous system (CNS) disorders. We generate in-house datasets from human models of patient biology and use a novel AI approach to map an untapped and unmapped frontier in neuroscience. Our discovery approach bypasses the need for a genetic diagnosis.